PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)

This study is comparing a new type of imaging scan (PET/MR using a tracer called [68Ga]Ga-PentixaFor that targets a protein called CXCR4) versus standard imaging to better detect and monitor multiple myeloma — a cancer of plasma cells in the bone marrow — especially in patients whose disease is harder to track with conventional tests. **You may be eligible if...** - You are 18 years old or older - You have a confirmed diagnosis of multiple myeloma — particularly a type that does not produce measurable proteins (nonsecretory or oligosecretory myeloma), or where there is suspicion of disease outside the bone marrow - You have not received extensive prior treatment **You may NOT be eligible if...** - You are pregnant or breastfeeding - You are unable to lie still in a scanner for at least 30 minutes - You have any contraindications for MRI (such as certain metal implants or pacemakers) - You have a known allergy to the imaging tracer used in the study - You have been diagnosed with another blood cancer (such as lymphoma or leukemia) at the same time Talk to your doctor to see if this trial is right for you.